Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albuzest is a high-protein nutritional supplement developed and marketed by Alniche Life Sciences, primarily composed of egg white (albumen) powder. It is specifically formulated to address protein deficiency in patients recovering from critical illness, surgery, or chronic infections. The product features a high-protein, low-fat profile with high bioavailability compared to other protein sources like whey, soy, or casein. In addition to egg albumen, Albuzest contains a blend of essential amino acids, including branched-chain amino acids (L-Leucine, L-Isoleucine, and L-Valine), as well as L-Glutamine, L-Arginine, Taurine, and Alpha-Lipoic acid. It is further fortified with a comprehensive mix of multivitamins and minerals. Specialized variants are available for specific clinical needs, such as Albuzest-Reno for renal care (kidney dialysis patients) and Albuzest-Hepa for hepatic and gastrointestinal care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albuzest.